FR2854158B1 - Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique - Google Patents

Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique

Info

Publication number
FR2854158B1
FR2854158B1 FR0305213A FR0305213A FR2854158B1 FR 2854158 B1 FR2854158 B1 FR 2854158B1 FR 0305213 A FR0305213 A FR 0305213A FR 0305213 A FR0305213 A FR 0305213A FR 2854158 B1 FR2854158 B1 FR 2854158B1
Authority
FR
France
Prior art keywords
phenylethiazole
acylamino
derivatives
preparation
therapeutic use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0305213A
Other languages
English (en)
French (fr)
Other versions
FR2854158A1 (fr
Inventor
Pierre Carayon
Pierre Casellas
Daniel Floutard
Pierre Fraisse
Samir Jegham
Bernard Labeeuw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0305213A priority Critical patent/FR2854158B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to EP04742558A priority patent/EP1656373B1/fr
Priority to PCT/FR2004/000981 priority patent/WO2004096798A2/fr
Priority to AU2004234101A priority patent/AU2004234101A1/en
Priority to MXPA05011522A priority patent/MXPA05011522A/es
Priority to BRPI0409716-5A priority patent/BRPI0409716A/pt
Priority to JP2006505808A priority patent/JP4839208B2/ja
Priority to AT04742558T priority patent/ATE541843T1/de
Priority to CNA2004800180511A priority patent/CN1826339A/zh
Priority to YUP-2005/0769A priority patent/RS20050769A/sr
Priority to RU2005136663/04A priority patent/RU2348630C2/ru
Priority to OA1200500305A priority patent/OA13049A/fr
Priority to CA002521158A priority patent/CA2521158A1/fr
Priority to KR1020057020168A priority patent/KR20060006935A/ko
Priority to ZA200508608A priority patent/ZA200508608B/en
Priority to ARP040101382A priority patent/AR044070A1/es
Priority to TW093111632A priority patent/TW200510325A/zh
Publication of FR2854158A1 publication Critical patent/FR2854158A1/fr
Priority to TNP2005000254A priority patent/TNSN05254A1/en
Priority to CR8037A priority patent/CR8037A/es
Priority to US11/253,998 priority patent/US7504511B2/en
Priority to EC2005006111A priority patent/ECSP056111A/es
Priority to NO20054905A priority patent/NO20054905L/no
Priority to MA28569A priority patent/MA27769A1/fr
Priority to CO05108740A priority patent/CO5640106A2/es
Application granted granted Critical
Publication of FR2854158B1 publication Critical patent/FR2854158B1/fr
Priority to US12/360,568 priority patent/US7777041B2/en
Priority to JP2011008854A priority patent/JP2011126891A/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
FR0305213A 2003-04-25 2003-04-25 Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique Expired - Fee Related FR2854158B1 (fr)

Priority Applications (26)

Application Number Priority Date Filing Date Title
FR0305213A FR2854158B1 (fr) 2003-04-25 2003-04-25 Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
CNA2004800180511A CN1826339A (zh) 2003-04-25 2004-04-22 2－酰氨基－4－苯基噻唑衍生物,其制备方法及其在治疗学上的应用
AU2004234101A AU2004234101A1 (en) 2003-04-25 2004-04-22 Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
MXPA05011522A MXPA05011522A (es) 2003-04-25 2004-04-22 Derivados de 2-acilamino-4-feniltiazol, metodo para su preparacion y su aplicacion en terapeutica.
BRPI0409716-5A BRPI0409716A (pt) 2003-04-25 2004-04-22 derivados de 2-acilamino-4-feniltiazol, seu preparo e sua aplicação em terapêutica
JP2006505808A JP4839208B2 (ja) 2003-04-25 2004-04-22 ２−アシルアミノ−４−フェニルチアゾール誘導体、それらの製造法およびそれらの治療用途
AT04742558T ATE541843T1 (de) 2003-04-25 2004-04-22 2-acylamino-4-phenylthiazolderivate, ihre herstellung und anwendung als chemokin antagonisten
PCT/FR2004/000981 WO2004096798A2 (fr) 2003-04-25 2004-04-22 Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique
YUP-2005/0769A RS20050769A (sr) 2003-04-25 2004-04-22 Derivati 2-acilamino-4- feniltiazola,postupak za njihovu pripremu i primena istih u lečenju
RU2005136663/04A RU2348630C2 (ru) 2003-04-25 2004-04-22 Производные 2-ациламино-4-фенилтиазола, их получение и их применение в терапии
OA1200500305A OA13049A (fr) 2003-04-25 2004-04-22 Dèrivès de 2-acylamino-4-phénylthiazole, leur préparation et leur application en thérapeutique.
CA002521158A CA2521158A1 (fr) 2003-04-25 2004-04-22 Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique
KR1020057020168A KR20060006935A (ko) 2003-04-25 2004-04-22 2-아실아미노-4-페닐티아졸 유도체, 그의 제조 방법 및치료학적 응용
ZA200508608A ZA200508608B (en) 2003-04-25 2004-04-22 Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
EP04742558A EP1656373B1 (fr) 2003-04-25 2004-04-22 Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur utilisation en tant qu'antagonistes des chimiokines
ARP040101382A AR044070A1 (es) 2003-04-25 2004-04-23 Derivados de 2 -acilamino -4- feniltiazol, su preparacion y su aplicacion en terapeutica
TW093111632A TW200510325A (en) 2003-04-25 2004-04-26 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
TNP2005000254A TNSN05254A1 (en) 2003-04-25 2005-10-06 Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
CR8037A CR8037A (es) 2003-04-25 2005-10-11 Derivados de 2- acilamino- 4- feniletiazol, su preparacion y su aplicacion en terapeutica
US11/253,998 US7504511B2 (en) 2003-04-25 2005-10-19 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
EC2005006111A ECSP056111A (es) 2003-04-25 2005-10-21 Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
NO20054905A NO20054905L (no) 2003-04-25 2005-10-24 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
MA28569A MA27769A1 (fr) 2003-04-25 2005-10-24 Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
CO05108740A CO5640106A2 (es) 2003-04-25 2005-10-25 Derivados de 2-acilamino -4-feniltiazol, su preparacion y su aplicacion en terapeutica
US12/360,568 US7777041B2 (en) 2003-04-25 2009-01-27 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
JP2011008854A JP2011126891A (ja) 2003-04-25 2011-01-19 ２−アシルアミノ−４−フェニルチアゾール誘導体の合成中間体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0305213A FR2854158B1 (fr) 2003-04-25 2003-04-25 Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2854158A1 FR2854158A1 (fr) 2004-10-29
FR2854158B1 true FR2854158B1 (fr) 2006-11-17

Family

ID=33104460

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0305213A Expired - Fee Related FR2854158B1 (fr) 2003-04-25 2003-04-25 Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique

Country Status (24)

Country Link
US (2) US7504511B2 (enExample)
EP (1) EP1656373B1 (enExample)
JP (2) JP4839208B2 (enExample)
KR (1) KR20060006935A (enExample)
CN (1) CN1826339A (enExample)
AR (1) AR044070A1 (enExample)
AT (1) ATE541843T1 (enExample)
AU (1) AU2004234101A1 (enExample)
BR (1) BRPI0409716A (enExample)
CA (1) CA2521158A1 (enExample)
CO (1) CO5640106A2 (enExample)
CR (1) CR8037A (enExample)
EC (1) ECSP056111A (enExample)
FR (1) FR2854158B1 (enExample)
MA (1) MA27769A1 (enExample)
MX (1) MXPA05011522A (enExample)
NO (1) NO20054905L (enExample)
OA (1) OA13049A (enExample)
RS (1) RS20050769A (enExample)
RU (1) RU2348630C2 (enExample)
TN (1) TNSN05254A1 (enExample)
TW (1) TW200510325A (enExample)
WO (1) WO2004096798A2 (enExample)
ZA (1) ZA200508608B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2676B1 (en) * 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2527B1 (en) * 2004-04-06 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines
FR2872813B1 (fr) 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
GB0421908D0 (en) * 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
FR2876692B1 (fr) * 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
EP1833807A1 (en) * 2005-01-05 2007-09-19 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
CN101137657B (zh) 2005-03-08 2011-02-02 詹森药业有限公司 作为神经激肽（nk1）拮抗剂的二氮杂-螺-[4.4]-壬烷衍生物
BRPI0608910A2 (pt) * 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
WO2007053495A2 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053498A1 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
FR2895989B1 (fr) 2006-01-06 2010-04-30 Sanofi Aventis Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
EP2059515A2 (en) * 2006-04-12 2009-05-20 Pfizer Limited Pyrrolidine derivatives as modulators of chemokine ccr5 receptors
RU2303597C1 (ru) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
CN101096363B (zh) 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
WO2008060621A2 (en) 2006-11-17 2008-05-22 Abbott Laboratories Aminopyrrolidines as chemokine receptor antagonists
SI2118099T1 (sl) * 2007-02-13 2011-11-30 Ab Science Postopek za sintezo 2-aminotiazolnih spojin kot kinaznih inhibitorjev
WO2008124000A2 (en) * 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
JP5164181B2 (ja) * 2007-07-31 2013-03-13 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物を含有する医薬組成物およびその中間体
CN103724328B (zh) 2008-12-19 2015-10-14 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
WO2011115998A2 (en) 2010-03-17 2011-09-22 Taivex Therapeutics Inc. Modulators of hec1 activity and methods therefor
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
CN103086859B (zh) * 2011-11-08 2015-11-11 清华大学 2,4-二羟基-5,6-取代-1-卤代苯衍生物、其合成方法及其应用
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
US11028061B2 (en) * 2015-07-27 2021-06-08 Sanford Burnham Prebys Medical Discovery Institute Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof
WO2019222393A1 (en) 2018-05-15 2019-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotective compositions and methods of using the same
WO2020086625A1 (en) * 2018-10-22 2020-04-30 The Regents Of The University Of California Vaccine adjuvant
CN112004798A (zh) * 2019-01-07 2020-11-27 江苏凯迪恩医药科技有限公司 一种苯甲酰胺类化合物、中间体、制备方法及应用
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE55034C (de) * H. KRÜGER in Berlin N., Artilleriestrafse 23 Zapfenverschlufs für chirurgische Instrumente
DD55034A (enExample) *
US3458526A (en) * 1966-09-26 1969-07-29 Upjohn Co Certain 2-amino-4,5-bis(p-methoxyphenyl)thiazoles
FR2296497A1 (fr) * 1974-12-31 1976-07-30 Asselin Robert Perfectionnement apporte aux fixations de verres optiques sur supports en vue de leur usinage
DE2706269C3 (de) * 1977-02-15 1979-08-02 Th. Goldschmidt Ag, 4300 Essen Verwendung von Aminderivaten zur Beeinflussung der Theologischen Eigenschaften von Bitumen und bituminösen Massen
FR2406634A1 (fr) * 1977-10-19 1979-05-18 Fabre Sa Pierre Immunostimulants derives d'amino thiazoles
JPH0717589B2 (ja) * 1990-01-22 1995-03-01 ファイザー製薬株式会社 新規１，３―ジカルボニル化合物およびその組成物
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
AU2000092A (en) 1991-06-21 1993-01-25 Boehringer Mannheim Italia S.P.A. 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract
GB9816837D0 (en) * 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
CA2136999C (en) * 1993-04-07 2004-05-11 Takafumi Fujioka Peripheral vasodilating agent containing piperidine derivative as active ingredient
DE4326344A1 (de) * 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6331545B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko Heterocycyclic piperidines as modulators of chemokine receptor activity
AU2001280187A1 (en) * 2000-08-28 2002-03-13 Toray Industries, Inc. Cyclic amine derivatives
CA2432713C (en) 2000-12-22 2009-10-27 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
JP4083422B2 (ja) * 2000-12-22 2008-04-30 石原産業株式会社 アニリン誘導体またはその塩ならびにそれらを含有するサイトカイン産生抑制剤
GB0104050D0 (en) * 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
US20030055263A1 (en) * 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
WO2003015778A1 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
JP2004256429A (ja) * 2003-02-26 2004-09-16 Sankyo Co Ltd イソキノリン誘導体
FR2872813B1 (fr) 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
FR2876692B1 (fr) 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
FR2895989B1 (fr) 2006-01-06 2010-04-30 Sanofi Aventis Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
EP1656373A2 (fr) 2006-05-17
ECSP056111A (es) 2006-03-01
WO2004096798A3 (fr) 2006-01-26
OA13049A (fr) 2006-11-10
TW200510325A (en) 2005-03-16
RU2348630C2 (ru) 2009-03-10
US7777041B2 (en) 2010-08-17
JP2011126891A (ja) 2011-06-30
US20090156574A1 (en) 2009-06-18
CA2521158A1 (fr) 2004-11-11
CN1826339A (zh) 2006-08-30
KR20060006935A (ko) 2006-01-20
FR2854158A1 (fr) 2004-10-29
US20060135575A1 (en) 2006-06-22
WO2004096798A2 (fr) 2004-11-11
ATE541843T1 (de) 2012-02-15
RS20050769A (sr) 2007-11-15
NO20054905D0 (no) 2005-10-24
CR8037A (es) 2008-07-29
AR044070A1 (es) 2005-08-24
CO5640106A2 (es) 2006-05-31
US7504511B2 (en) 2009-03-17
ZA200508608B (en) 2007-01-31
JP4839208B2 (ja) 2011-12-21
JP2006524669A (ja) 2006-11-02
EP1656373B1 (fr) 2012-01-18
TNSN05254A1 (en) 2007-07-10
MA27769A1 (fr) 2006-02-01
AU2004234101A1 (en) 2004-11-11
MXPA05011522A (es) 2006-01-23
RU2005136663A (ru) 2006-03-20
BRPI0409716A (pt) 2006-05-02
NO20054905L (no) 2006-01-25

Similar Documents

Publication Publication Date Title
FR2854158B1 (fr) Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
FR2864080B1 (fr) Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
FR2854633B1 (fr) Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
FR2872813B1 (fr) Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
MA29017B1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
MA28575B1 (fr) Derives de la 1-amino-phthalazine, leur preparation , et leur application en therapeutique
MA27049A1 (fr) Derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2843964B1 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
FR2873691B1 (fr) Derives d'amino-piperidine, leur preparation et leur application en therapeutique
FR2882054B1 (fr) Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
MA27233A1 (fr) Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique
FR2856684B1 (fr) Derives de diphenylpyridine, leur preparation et leur application en therapeutique
FR2850377B1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2865205B1 (fr) Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866885B1 (fr) Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
FR2873690B1 (fr) Derives d'oxopiperidine, leur preparation et leur application en therapeutique
FR2891828B1 (fr) Derives de la 1-amino-phtalazine substituee, leur preparation et leur application en therapeutique
FR2888847B1 (fr) Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2860792B1 (fr) Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
FR2870846B1 (fr) Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
FR2845388B1 (fr) Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
FR2888848B1 (fr) Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2873693B1 (fr) Derives d'amino-tropane, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20101230